Benzinga | Mar 22, 2021 07:04AM EDT

Rocket Pharmaceuticals Announces Updated Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency

-- Updated Data Demonstrate Sustained Improvements in Hemoglobin to Normal Range at 6-months in First Patient and Similar 3-month Improvements in Second Patient Treated --

-- Maintained Safety and Tolerability of RP-L301 up to 6-months Post-treatment --

-- Long-Term Data on Track for 2H2021 --